Immunology and Biotherapies
25.6K views | +20 today
Follow
 
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert C FAURE's insight:

We choose Scoop.it as preferred curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Cell therapy bioprocessing: Moving toward commercial scale and efficiency - WHITEPAPER

Cell therapy bioprocessing: Moving toward commercial scale and efficiency - WHITEPAPER | Immunology and Biotherapies | Scoop.it
At the time of writing there are 672 cell and gene therapy companies worldwide and 20 products approved by the food and drug administration (FDA). Dendreon’s Provenge autologous cell therapy although approved by the FDA ultimately failed commercially due to a manufacturing and distribution model that was not efficient. Cost of Goods (CoGs), manufacturing process and logistics are critical to the success of cell therapy commercialisation and these need to be considered from the inception of a cell therapy company in addition to the clinical science. Three key enablers for success are manufacturing automation/ single use technologies, a diverse pipeline in modularised facilities, and sophisticated data acquisition/ logistics. This whitepaper explores the ways that progress towards commercial scale and efficiency in cell therapy bioprocessing is happening. To download the whitepaper simply log in or register for a KNect365 account, which will give you access to all our exclusive premium content.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

A Complete Workflow Solution for Intact Monoclonal Antibody Characterization Using a New High-Performance Benchtop Quadrupole-Orbitrap LC-MS/MS

A Complete Workflow Solution for Intact Monoclonal Antibody Characterization Using a New High-Performance Benchtop Quadrupole-Orbitrap LC-MS/MS | Immunology and Biotherapies | Scoop.it
Purpose: A LC/MS-based workflow solution was developed for robust, accurate and comprehensive intact monoclonal antibody (mAb) characterization.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New hope for stem cell approach to treating diabetes –

New hope for stem cell approach to treating diabetes – | Immunology and Biotherapies | Scoop.it
Insulin-producing cells more responsive to fluctuating glucose levels...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Experimental treatment approach shows potential against Staphylococcus aureus

Experimental treatment approach shows potential against Staphylococcus aureus | Immunology and Biotherapies | Scoop.it
A new class of engineered proteins may counter infection caused by Staphylococcus aureus - a bacterial species considered one of the largest global health threats, a new study suggests.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Comparable Outcome with a Faster Engraftment of Optimized Haploidentical Hematopoietic Stem Cell Transplantation Compared to Transplantations from Other Donor Types in Pediatric Acquired Aplastic A...

Comparable Outcome with a Faster Engraftment of Optimized Haploidentical Hematopoietic Stem Cell Transplantation Compared to Transplantations from Other Donor Types in Pediatric Acquired Aplastic A... | Immunology and Biotherapies | Scoop.it
Severe aplastic anemia (SAA) is a life-threatening disorder for which allogeneic hematopoietic
stem cell transplantation (HCT) is a curative treatment. Human leukocyte antigen (HLA)-matched sibling donors (MSD) are the preferred donors; however, it is not always possible to find an MSD for...
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: A systematic review and meta-analysis. - PubMed - NCBI

PLoS One. 2018 Jul 19;13(7):e0201025. doi: 10.1371/journal.pone.0201025. eCollection 2018.Meta-Analysis; Systematic Review...
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review and Collection
Scoop.it!

Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors

Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors | Immunology and Biotherapies | Scoop.it
Most solid tumors are comprised of multiple clones that express orthogonal antigens, suggesting that novel strategies must be developed in order to adapt chimeric antigen receptor (CAR) T-cell therapies to treat heterogeneous solid tumors.

Via Krishan Maggon
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Conversion of breast cancer cells into fat cells impedes the formation of metastases | University of Basel

Conversion of breast cancer cells into fat cells impedes the formation of metastases | University of Basel | Immunology and Biotherapies | Scoop.it
An innovative combination therapy can force malignant breast cancer cells to turn into fat cells. This can be used to prevent the formation of metastases in mice, as researchers at the University of Basel’s Department of Biomedicine recently reported in the journal Cancer Cell.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gut microbes from healthy infants block milk allergy development in mice

Gut microbes from healthy infants block milk allergy development in mice | Immunology and Biotherapies | Scoop.it
New research suggests that the gut microbiome may help prevent the development of cow's milk allergy. Scientists found that gut microbes from healthy human infant donors transplanted into mice protected animals exposed to milk from experiencing allergic reactions, while gut microbes transplanted...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

IL-33 Augments Virus-Specific Memory T Cell Inflation and Potentiates the Efficacy of an Attenuated Cytomegalovirus-Based Vaccine

IL-33 Augments Virus-Specific Memory T Cell Inflation and Potentiates the Efficacy of an Attenuated Cytomegalovirus-Based Vaccine | Immunology and Biotherapies | Scoop.it
Abstract
Candidate vaccines designed to generate T cell–based immunity are typically vectored by nonpersistent viruses, which largely fail to elicit durable effector memory T cell responses. This limitation can be overcome using recombinant strains of CMV. Proof-of-principle studies have demonstrated the potential benefits of this approach, most notably in the SIV model, but safety concerns require the development of nonreplicating alternatives with comparable immunogenicity. In this study, we show that IL-33 promotes the accumulation and recall kinetics of circulating and tissue-resident memory T cells in mice infected with murine CMV. Using a replication-deficient murine CMV vector, we further show that exogenous IL-33 boosts vaccine-induced memory T cell responses, which protect against subsequent heterologous viral challenge. These data suggest that IL-33 could serve as a useful adjuvant to improve the efficacy of vaccines based on attenuated derivatives of CMV.
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Human Cartilage‐Derived Progenitors Resist Terminal Differentiation and Require CXCR4 Activation to Successfully Bridge Meniscus Tissue Tears - Jayasuriya - 2019 - STEM CELLS - Wiley Online Library

STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. STEM CELLS is read and written by clinical and basic scientists whose expertise encompasses the rapidly expanding fields of stem and progenitor cell...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis | BMC Medicine | Full Text

The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis | BMC Medicine | Full Text | Immunology and Biotherapies | Scoop.it
Conflicting results regarding the impact of repeated vaccination on influenza vaccine effectiveness (VE) may cause confusion regarding the benefits of receiving the current season’s vaccine. We systematically searched MEDLINE, Embase, PubMed, and Cumulative Index to Nursing and Allied Health Literature from database inception to August 17, 2016, for observational studies published in English that reported VE against laboratory-confirmed influenza for the following four vaccination groups: current season only, prior season only, both seasons, and neither season. We pooled differences in VE (∆VE) between vaccination groups by influenza season and type/subtype using a random-effects model. The study protocol is registered with PROSPERO (registration number: CRD42016037241). We identified 3435 unique articles, reviewed the full text of 634, and included 20 for meta-analysis. Compared to prior season vaccination only, vaccination in both seasons was associated with greater protection against influenza H1N1 (∆VE = 25%; 95% CI 14%, 35%) and B (∆VE = 18%; 95% CI 3%, 33%), but not H3N2 (∆VE = 7%; 95% CI – 7%, 21%). Compared to no vaccination for either season, individuals who received the current season’s vaccine had greater protection against H1N1 (∆VE = 62%; 95% CI 51%, 70%), H3N2 (∆VE = 45%; 95% CI 35%, 53%), and B (∆VE = 64%; 95% CI 57%, 71%). We observed no differences in VE between vaccination in both seasons and the current season only for H1N1 (∆VE = 3%; 95% CI – 8%, 13%), but less protection against influenza H3N2 (∆VE = − 20%; 95% CI – 36%, − 4%), and B (∆VE = − 11%; 95% CI – 20%, − 2%). Our results support current season vaccination regardless of prior season vaccination because VE for vaccination in the current season only is higher compared to no vaccination in either season for all types/subtypes, and for H1N1 and influenza B, vaccination in both seasons provides better VE than vaccination in the prior season only. Although VE was lower against H3N2 and B for individuals vaccinated in both seasons compared to those vaccinated in the current season only, it should be noted that past vaccination history cannot be altered and this comparison disregards susceptibility to influenza during the prior season among those vaccinated in the current season only. In addition, our results for H3N2 were particularly influenced by the 2014–2015 influenza season and the impact of repeated vaccination for all types/subtypes may vary from season to season. It is important that future VE studies include vaccination history over multiple seasons to evaluate repeated vaccination in more detail.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Leukocytoclastic vasculitis with purpura and renal failure induced by the anti-epidermal growth factor receptor antibody panitumumab: a case report | Journal of Medical Case Reports | Full Text

Leukocytoclastic vasculitis with purpura and renal failure induced by the anti-epidermal growth factor receptor antibody panitumumab: a case report | Journal of Medical Case Reports | Full Text | Immunology and Biotherapies | Scoop.it
Panitumumab is the first human combinatorial antibody for the treatment of metastatic colorectal carcinoma. Dermatologic toxicity of all grades occurs in more than 90% of patients. However, there are few reports of purpura induced by anti-epidermal growth factor receptor antibody.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Developing A Treatment | ASGCT - American Society of Gene & Cell Therapy

Developing A Treatment | ASGCT - American Society of Gene & Cell Therapy | Immunology and Biotherapies | Scoop.it
Developing A Treatment New therapies spend a lot of time being tested in labs and animals in preclinical studies before making it to patients. By the time the therapy enters human clinical trials, it is better understood and ready for further development. Learn more information about the process of developing a treatment. FDA Efforts Between preclinical study and clinical trials, the process can take many years to conclude. Clinical trials alone sometimes can take eight years or more. There are many variables that go into that duration including study planning, authorization to run a trial, ethics review, funding, research materials such as patient information, consent forms and monitoring systems. However, the U.S. Food and Drug Administration (FDA) is putting an effort into various expedited pathways to accelerate the process while still maintaining safety. Sometimes the typically described three phases of a clinical trial are combined to make the evaluation process more efficient. For serious and rare diseases where there is a clear unmet medical need and very few patients, the treatment may be made available more quickly. It’s worth noting that there are challenges associated with streamlining the clinical trial process. Researchers need to ensure that they avoid exposing multiple patients to suboptimal or toxic doses. Or, they need enough time to properly interpret the outcomes of a trial. It all goes back to making sure that the treatment is well understood, safe and effective enough to be approved for market. Speeding up the availability of drugs that treat serious diseases is in everyone’s interest. That’s why the FDA has created five different approaches to accelerating the development of treatment, they're called "expidited pathways." Some of these approaches can be combined to make the development of treatment even more efficient. However, the names of these different approaches all sound, well, fast. So what is the difference between them? Expedited Pathways Accelerated Approval SHOW ANSWER Breakthrough Therapy SHOW ANSWER Fast Track SHOW ANSWER RMAT Designation SHOW ANSWER Priority Review SHOW ANSWER Not all research transpires in the United States, so there are global approval bodies similar to the FDA. National governments are responsible for establishing strong national medicines regulatory authorities, also known as MRAs. You may also see the phases of clinical trial referred to as early, late and pivotal stages of development. Patient Access Once a treatment successfully passes through clinical trials and is approved by the FDA, then what happens? How can patients access the treatments? There were three gene therapies approved in 2017, so we’ll use those as our starting point - Luxturna, Yescarta and Kymriah. These therapies are offered at a limited number of sites, currently only at specialized academic medical centers. Although patients can reach out directly to a treatment center that offers the therapy, it’s important to inform their primary medical practitioner of the decision. Most times a clinician that knows the individual best will help in determining if the treatment is applicable and then may set up the referral. This primary clinician can also be involved in post-procedure care and answering questions along the way. The currently available gene therapies are covered by many health insurance options, including Medicare. Interested patients should contact their health insurance provider to determine its coverage, as well as what to expect as far as out-of-pocket costs. Manufacturers of the gene therapies often offer patient support services to assist in navigating the process. One of the most important components to moving along research and development of these therapies are the many volunteers that participate in clinical trials every year. Thanks to the volunteers, more people are living longer, healthier lives. Participating in clinical trials is a way to receive an investigational treatment at no cost, while benefiting the medical community, and others who have the same disease or condition. According to a study from CISCRP, 94 percent of people who have participated in a clinical trial of some type would be willing to participate again or would recommend others to participate. Finding a Clinical Trial Patients can access gene or cell therapy treatment by participating in a clinical trial. Not only can you potentially receive treatment for a disease, you can also help the greater good by assisting researchers in their studies. Talk to your Doctor: even if you find a clinical trial on your own, it is still important to speak with your doctor about it. Visit ClinicalTrials.gov: this clinical trial navigation service is a national database of treatment trials from different sponsors. Sign Up for a Patient Registry: patient registries are a collection of information about patients who share a condition or experience. Their goal is to help medical researchers better understand how diseases develop and progress over time. Some registries invite people to sign up to be contacted about participating in clinical research. Here’s a helpful list of patient registries from the National Institutes of Health (NIH).  Patient Advocacy Organizations: these organizations are hard at work to support rare genetic diseases and can be a great way to get involved and advocate for a disease. It is also a valuable source for emotional support, advice, and to learn others’ experiences with clinical trials. Download as PDF
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gene Therapy Basics | Education | ASGCT American Society of Gene & Cell Therapy | ASGCT - American Society of Gene & Cell Therapy

Gene Therapy Basics | Education | ASGCT American Society of Gene & Cell Therapy | ASGCT - American Society of Gene & Cell Therapy | Immunology and Biotherapies | Scoop.it
Gene therapy has been studied for more than 40 years and can help stop or slow the effects of disease on the most basic level of the human body—our genes. And to understand how it works, ASGCT starts at the basics.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Regulation and potential drug targets of tumor-associated Tregs

Regulation and potential drug targets of tumor-associated Tregs | Immunology and Biotherapies | Scoop.it
According to estimates from the World Health Organization (WHO), there will be 18.1 million new cases and 9.6 million cancer deaths worldwide in 2018. Cancer is a serious disease that affects people all over the world.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Sanofi Scientists Imagine a World Without Diabetes | Sanofi - Sanofi

Sanofi Scientists Imagine a World Without Diabetes | Sanofi - Sanofi | Immunology and Biotherapies | Scoop.it
At Sanofi, science is our passion.To mark the 78th Scientific Sessions of the American Diabetes Association in June, we are spotlighting the work of our...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Comparison of outcomes of frontline immunosuppressive therapy and frontline haploidentical hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched s...

Comparison of outcomes of frontline immunosuppressive therapy and frontline haploidentical hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched s... | Immunology and Biotherapies | Scoop.it
Severe aplastic anemia (SAA) is a hematopoietic failure disorder caused by the destruction
of hematopoietic stem cell cloning due to immune abnormalities, and severe bleeding
and infection are the main causes of death.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board

Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential
in cancer therapy. An article by the Vivier group (Cell 2018;175:1731–1743) shows
that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible
in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and
PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights
Scoop.it!

Mesenchymal stems cells: Vital role in repair of damaged organs

Mesenchymal stems cells: Vital role in repair of damaged organs | Immunology and Biotherapies | Scoop.it
In adults, mesenchymal stems cells (MSCs) are primarily found in bone marrow and they play a vital role in repair of damaged organs. The transformation of a single MSC into complex tissue like cartilage and bone starts with its association with other MSCs in order to form microscopic clusters via...

Via Krishan Maggon
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The Future Of Anti-BCMA CAR-T Cell Therapy

The Future Of Anti-BCMA CAR-T Cell Therapy | Immunology and Biotherapies | Scoop.it
Habte Yimer, MD Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, discusses The Future Of Anti-BCMA CAR-T Cell Therapy. At The 60th ASH Annual Meeting on Dec 1, 2018.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

IJMS |  Zinc Up-Regulates Insulin Secretion from β Cell-Like Cells Derived from Stem Cells from Human Exfoliated Deciduous Tooth (SHED)

IJMS |  Zinc Up-Regulates Insulin Secretion from β Cell-Like Cells Derived from Stem Cells from Human Exfoliated Deciduous Tooth (SHED) | Immunology and Biotherapies | Scoop.it
Stem cells from human exfoliated deciduous tooth (SHED) offer several advantages over other stem cell sources. Using SHED, we examined the roles of zinc and the zinc uptake transporter ZIP8 (Zrt- and irt-like protein 8) while inducing SHED into insulin secreting β cell-like stem cells (i.e.,...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Nanovaccine: A novel approach in immunization - Gheibi Hayat - - Journal of Cellular Physiology - Wiley Online Library

Abstract
Despite great advances in the field of vaccination, there are still needs for novel and effective vaccines because still no effective vaccines have been produced for some diseases such as malaria, acquired immune deficiency syndrome (AIDS), and tuberculosis. Furthermore, many of the existing vaccines have disadvantages such as failure to stimulate completely the immune system, in vivo instability, high toxicity, the need for cold chain, and multiple administrations. Nanotechnology has been raised as a powerful tool for solving these problems in this regard. Generally, nanovaccines are a new generation of vaccines using nanoparticles (NPs) as carriers and/or adjuvants. Due to the similar scale (size) between the NPs and pathogens, the immune system can be stimulated well, resulting in triggered cellular and humoral immunity responses. Other benefits of the nanovaccines include their better stability in blood flow to increase the shelf life in blood, enhanced immune system stimulation, no need for booster doses, no need to maintain the cold chain, and ability to create active targeting. In addition, nanovaccines have raised the hope to treat diseases such as rheumatoid arthritis, AIDS, malaria, and chronic autoimmune, and so forth.
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Peptides as Therapeutic Agents for Inflammatory-Related Diseases. - PubMed - NCBI

Int J Mol Sci. 2018 Sep 11;19(9). pii: E2714. doi: 10.3390/ijms19092714.Review...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Home : Grand Challenges in Immunology: Immunotherapy for Cancer and Beyond

Home : Grand Challenges in Immunology: Immunotherapy for Cancer and Beyond | Immunology and Biotherapies | Scoop.it
Nature - the world's best science and medicine on your desktop...
more...
No comment yet.